Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

被引：0
|
作者：
Bennouna, J. [1 ]
Hiret, S. [2 ]
Borg, C. [3 ]
Bertaut, A. [4 ]
Bouche, O. [5 ]
Deplanque, G. [6 ]
Francois, E. [7 ]
Conroy, T. [8 ]
Ghiringhelli, F. [9 ]
des Guetz, G. [10 ]
Seitz, J-F. [11 ]
Artru, P. [12 ]
Stanbury, T. [13 ]
Charpentier, S. [14 ]
Denis, M. [14 ]
Adenis, A. [15 ]
机构：
[1] CHU Nantes, IMAD Digest Oncol, Nantes, France
[2] Inst Cancerol Ouest, Med Oncol, St Herblain, France
[3] CHU Besancon, Med Oncol, Besancon, France
[4] Georges Francois Leclerc Canc Ctr, Biostat, Dijon, France
[5] CHU Reims, Gastroenterol, Reims, France
[6] Hop Riviera Chablais, Med Oncol, Vevey, Switzerland
[7] Ctr Antoine Lacassagne, Med Oncol, Nice, France
[8] Inst Cancerol Lorraine, Med Oncol, Vandoeuvre Les Nancy, France
[9] Georges Francois Leclerc Canc Ctr, Med Oncol, Dijon, France
[10] CHU St Denis, Med Oncol, Limoges, France
[11] APHM, Gastroenterol, Marseille, France
[12] Hop Prive Jean Mermoz, Gastroenterol, Lyon, France
[13] UNICANCER, Invest Ctr, Paris, France
[14] CHU Nantes, Mol Biol, Nantes, France
[15] Ctr Oscar Lambret, Med Oncol, Lille, France
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
477O
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18-UNICANCER GI).
    Hiret, Sandrine
    Borg, Christophe
    Bertaut, Aurelie
    Bouche, Olivier
    Adenis, Antoine
    Deplanque, Gael
    Francois, Eric
    Conroy, Thierry
    Ghiringhelli, Francois
    Des Guetz, Gaetan
    Seitz, Jean-Francois
    Artru, Pascal
    Stanbury, Trevor
    Denis, Marc G.
    Bennouna, Jaafar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer The UNICANCER PRODIGE18 Randomized Clinical Trial
    Bennouna, Jaafar
    Hiret, Sandrine
    Bertaut, Aurelie
    Bouche, Olivier
    Deplanque, Gael
    Borel, Christian
    Francois, Eric
    Conroy, Thierry
    Ghiringhelli, Francois
    des Guetz, Gaetan
    Seitz, Jean-Francois
    Artru, Pascal
    Hebbar, Mohamed
    Stanbury, Trevor
    Denis, Marc G.
    Adenis, Antoine
    Borg, Christophe
    [J]. JAMA ONCOLOGY, 2019, 5 (01) : 83 - 90
  • [3] Chemotherapy plus panitumumab/cetuximab versus chemotherapy plus bevacizumab in wild-type KRAS/RAS metastatic colorectal cancer: a meta-analysis
    Zhang, Chengren
    Liu, Lili
    Lv, Yaochun
    Li, Jingjing
    Cao, Cong
    Lu, Jiyong
    Wang, Shuai
    Du, Binbin
    Yang, Xiongfei
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (12) : 1333 - 1348
  • [4] Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.
    Antoniotti, Carlotta
    Cremolini, Chiara
    Loupakis, Fotios
    Bergamo, Francesca
    Grande, Roberta
    Tonini, Giuseppe
    Garattini, Silvio Ken
    Masi, Gianluca
    Battaglin, Francesca
    Lucchesi, Sara
    Salvatore, Lisa
    Corsi, Domenico C.
    Di Fabio, Francesca
    Banzi, Maria
    Sensi, Elisa
    Tomcikova, Daniela
    Fontanini, Gabriell
    Zagonel, Vittorina
    Boni, Luca
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Continuing Cetuximab vs Bevacizumab plus chemotherapy after first progression in wild-type KRAS, NRAS and BRAF V600E metastatic colorectal cancer: a randomized phase II trial
    Li, Danyang
    Wang, Feng
    Xu, Shuning
    Li, Ke
    Meng, Xiangrui
    Huang, Yangyang
    Ma, Ning
    Qiao, Lei
    Kuang, Gaizhen
    Chen, Jinghong
    Liu, Ying
    [J]. JOURNAL OF CANCER, 2021, 12 (17): : 5268 - 5274
  • [6] Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer
    Azadeh, Payam
    Mortazavi, Nafiseh
    Tahmasebi, Arezoo
    Kamal, Farnaz Hosseini
    Novin, Kambiz
    [J]. CHEMOTHERAPY, 2015, 61 (01) : 51 - 56
  • [7] Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): The phase II randomized MACBETH trial by GONO
    Cremolini, C.
    Antoniotti, C.
    Loupakis, F.
    Bergamo, F.
    Ferrari, L.
    Grande, R.
    Tonini, G.
    Masi, G.
    Schirripa, M.
    Bonotto, M.
    Solda, C.
    Lucchesi, S.
    Rossini, D.
    Corsi, D.
    Ronzoni, M.
    Llimpe, F. L. Rojas
    Fontanini, G.
    Boni, L.
    Zagonel, V.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [8] FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial
    Falcone, A.
    Cremolini, C.
    Loupakis, F.
    Lonardi, S.
    Casagrande, M. E.
    Murgioni, S.
    Salvatore, L.
    Masi, G.
    Fanotto, V.
    Granetto, C.
    Marmorino, F.
    Ginocchi, L.
    Ziampiri, S.
    Grande, R.
    Tonini, G.
    Delfanti, S.
    Di Donato, S.
    Fontanini, G.
    Boni, L.
    Zagonel, V.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [9] Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): the phase II randomized MACBETH trial by GONO
    Antoniotti, C.
    Cremolini, C.
    Loupakis, F.
    Bergamo, F.
    Garattini, S. K.
    Grande, R.
    Tonini, G.
    Masi, G.
    Schirripa, M.
    Bonotto, M.
    Ruman, L.
    Lucchesi, S.
    Rossini, D.
    Corsi, D.
    Ronzoni, M.
    Llimpe, F. L. Rojas
    Fontanini, G.
    Boni, L.
    Zagonel, V.
    Delliponti, L.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [10] PRODIGE 20: Bevacizumab plus chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)-A randomized phase II trial.
    Aparicio, Thomas
    Bouche, Olivier
    Francois, Eric
    Maillard, Emilie
    Kirscher, Sylvie
    Taieb, Julien
    Etienne, Pierre-Luc
    Faroux, Roger
    Khemissa, Faiza
    El Hajbi, Farid
    Locher, Christophe
    Rinaldi, Yves
    Lecomte, Thierry
    Lavau-Denes, Sandrine
    Baconnier, Mathieu
    Oden-Gangloff, Alice
    Genet, Dominique
    Paillaud, Elena
    Retornaz, Frederic
    Bedenne, Laurent
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345